Clinical Trial Update: A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

Phase III trial update evaluating SHR-A1811 with or without pertuzumab in HER2-positive breast cancer that is recurrent or metastatic; study status is active bu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Perjeta (pertuzumab)
• SHR-A1811

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: HER2-PositiveRecurrent or Metastatic Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING